Publications

  1. Kottschade LA. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Curr Oncol Rep. 2018 Mar 6; 20 (3):24 Epub 2018 Mar 06
    View PubMed
  2. Richter MD, Pinkston O, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. Arthritis Rheumatol. 2018 Mar; 70 (3):356-360 Epub 2018 Feb 06
    View PubMed
  3. McWilliams RR, Allred JB, Slostad JA, Katipamula R, Dronca RS, Rumilla KM, Erickson LA, Bryce AH, Joseph RW, Kottschade LA, King DM, Leitch JM, Markovic SN. NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab +/- everolimus for metastatic melanoma. Cancer. 2018 Feb 1; 124 (3):537-545 Epub 2017 Oct 17
    View PubMed
  4. Jakub JW, Racz JM, Hieken TJ, Gonzalez AB, Kottschade LA, Markovic SN, Yan Y, Block MS. Neoadjuvant systemic therapy for regionally advanced melanoma. J Surg Oncol. 2017 Dec 11 [Epub ahead of print]
    View PubMed
  5. Enninga EAL, Moser JC, Weaver AL, Markovic SN, Brewer JD, Leontovich AA, Hieken TJ, Shuster L, Kottschade LA, Olariu A, Mansfield AS, Dronca RS. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011. Cancer Med. 2017 Oct; 6 (10):2203-2212 Epub 2017 Sept 06
    View PubMed
  6. Youland RS, Blanchard ML, Dronca R, Kottschade L, Markovic SN, Olivier KR, Park SS. Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. Clin Transl Radiat Oncol. 2017 Oct; 6:25-30 Epub 2017 Sept 30
    View PubMed
  7. Alhammad RM, Dronca RS, Kottschade LA, Turner HJ, Staff NP, Mauermann ML, Tracy JA, Klein CJ. Brachial Plexus Neuritis Associated With Anti–Programmed Cell Death-1 Antibodies: Report of 2 Cases Mayo Clin Proc.2017;1:(2):192-197.
  8. Leon-Ferre RA, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, Allred JB, Lowe VJ, Markovic SN. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017 Aug; 27: (4)335-341.
    View PubMed
  9. Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab. 2017 Aug 1; 102 (8):2770-2780
    View PubMed
  10. Kottschade LA, Lehner Reed M. Promoting Oral Therapy Adherence: Consensus Statements From the Faculty of the Melanoma Nursing Initiative on Oral Melanoma Therapies. Clin J Oncol Nurs. 2017 Aug 1; 21 (4 Suppl):87-96
    View PubMed
  11. Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management. Am J Clin Oncol. 2017 Jul 26;
    View PubMed
  12. Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017 Apr; 75:47-55 Epub 2017 Feb 17
    View PubMed
  13. Youland RS, Packard AT, Blanchard MJ, Arnett AL, Wiseman GA, Kottschade LA, Dronca RS, Markovic SN, Olivier KR, Park SS. 18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma. Adv Radiat Oncol. 2017 Apr-Jun; 2: (2)204-210.
    View PubMed
  14. Leontovich AA, Dronca RS, Nevala WK, Thompson MA, Kottschade LA, Ivanov LV, Markovic SN, Melanoma Study Group of the Mayo Clinic Cancer Center. Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients. Melanoma Res. 2017 Feb; 27 (1):32-42
    View PubMed
  15. Failing JJ, Finnes HD, Kottschade LA, Allred JB, Markovic SN. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Res. 2016 Dec; 26 (6):609-615
    View PubMed
  16. Kottschade L, Brys A, Peikert T, Ryder M, Raffals L, Brewer J, Mosca P, Markovic S, Midwest Melanoma Partnership. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res. 2016 Oct; 26 (5):469-80
    View PubMed
  17. Kottschade L, Novotny P, Lyss A, Mazurczak M, Loprinzi C, Barton D. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). Support Care Cancer. 2016 Jun; 24: (6)2661-7.
    View PubMed
  18. Kottschade LA, McWilliams RR, Markovic SN, Block MS, Villasboas Bisneto J, Pham AQ, Esplin BL, Dronca RS. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016 Jun; 26 (3):300-3
    View PubMed
  19. Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight. 2016 May 05; 1: (6).
    View PubMed
  20. Jatoi A, Muss H, Allred JB, Cohen HJ, Ballman K, Hopkins JO, Gajra A, Lafky J, Wolff A, Kottschade L, Gralow J, Hurria A. Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). Psychooncology. 2016 Apr; 25: (4)441-6.
    View PubMed
  21. White ML, Atwell TD, Kurup AN, Schmit GD, Carter RE, Geske JR, Kottschade LA, Pulido JS, Block MS, Jakub JW, Callstrom MR, Markovic SN. Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma. Mayo Clin Proc. 2016 Mar; 91: (3)288-96.
    View PubMed
  22. De Felice KM, Gupta A, Rakshit S, Khanna S, Kottschade LA, Finnes HD, Papadakis KA, Loftus EV Jr, Raffals LE, Markovic SN. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015 Aug; 25 (4):321-7
    View PubMed
  23. Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol. 2015 Jun; 38: (3)252-8.
    View PubMed
  24. Gummadi T, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, Dudek AZ. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res. 2015 Feb; 25: (1)75-9.
    View PubMed
  25. Kottschade LA, Grotz TE, Dronca RS, Salomao DR, Pulido JS, Wasif N, Jakub JW, Bagaria SP, Kumar R, Kaur JS, Morita SY, Moran SL, Nguyen JT, Nguyen EC, Hand JL, Erickson LA, Brewer JD, Baum CL, Miller RC, Swanson DL, Lowe V, Markovic SN. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol. 2014 Dec; 37: (6)635-41.
    View PubMed
  26. Barton DL, Thanarajasingam G, Sloan JA, Diekmann B, Fuloria J, Kottschade LA, Lyss AP, Jaslowski AJ, Mazurczak MA, Blair SC, Terstriep S, Loprinzi CL. Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer. 2014 Nov 15; 120: (22)3575-83.
    View PubMed
  27. Smith EM, Campbell G, Tofthagen C, Kottschade L, Collins ML, Warton C, Ghosh B, Ronis DL, Mallory GA, Visovsky C. Nursing knowledge, practice patterns, and learning preferences regarding chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2014 Nov 1; 41(6):669-79.
    View PubMed
  28. Grotz TE, Kottschade L, Pavey ES, Markovic SN, Jakub JW. Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study. Am J Clin Oncol. 2014 Oct; 37: (5)467-72.
    View PubMed
  29. Kottschade LA, Bell J, Klinger K, Smith EM. Nursing's presence in the changing cooperative group setting. Semin Oncol Nurs. 2014 Feb; 30: (1)32-7.
    View PubMed
  30. Barton DL, Burger K, Novotny PJ, Fitch TR, Kohli S, Soori G, Wilwerding MB, Sloan JA, Kottschade LA, Rowland KM Jr, Dakhil SR, Nikcevich DA, Loprinzi CL. The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer. 2013 Apr; 21: (4)1185-92.
    View PubMed
  31. Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML, Markovic SN. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer. 2013 Feb 01; 119: (3)586-92.
    View PubMed
  32. Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, Markovic SN. Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc. 2012 Oct; 87: (10)976-81.
    View PubMed
  33. Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, Thompson MA, Robinson A, Kottschade LA, Kaur JS, McWilliams RR, Ivanov LV, Croghan GA, Markovic SN. Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed). 2012; 4:958-75. Epub 2012 Jan 01.
    View PubMed
  34. Grotz TE, Mansfield AS, Kottschade LA, Erickson LA, Otley CC, Markovic SN, Jakub JW. In-transit melanoma: an individualized approach. Oncology (Williston Park). 2011 Dec; 25(14):1340-8.
    View PubMed
  35. Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer. 2011 Nov; 19 (11):1769-77 Epub 2010 Oct 09
    View PubMed
  36. Block MS, Suman VJ, Nevala WK, Kottschade LA, Creagan ET, Kaur JS, Quevedo JF, McWilliams RR, Markovic SN. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res. 2011 Oct; 21(5):438-45.
    View PubMed
  37. Loprinzi CL, Balcueva EP, Liu H, Sloan JA, Kottschade LA, Stella PJ, Carlson MD, Moore DF Jr, Zon RT, Levitt R, Jaslowski AJ. A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA. J Support Oncol. 2011 May-Jun; 9: (3)105-12.
    View PubMed
  38. Kottschade LA, Suman VJ, Amatruda T 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer. 2011 Apr 15; 117: (8)1704-10.
    View PubMed
  39. Kottschade LA, Weenig RH, Otley CC, McWilliams RR, Markovic SN. The use of pulsed dye laser in the treatment of melanoma metastatic to the skin: aMayo Clinic case series. J Am Acad Dermatol. 2010; 62(6).
    View PubMed
  40. Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM Jr, Atherton PJ, Marsa GW, Knutson WH, Bearden JD 3rd, Kottschade L, Fitch TR. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol. 2009 Mar; 20: (3)542-9.
    View PubMed
  41. Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR, Melanoma Study. Metastatic malignant melanoma. G Ital Dermatol Venereol. 2009 Feb; 144(1):1-26.
    View PubMed
  42. Perez DG, Suman VJ, Fitch TR, Amatruda T, Morton RF, Jilani SZ, Constantinou CL, Egner JR, Kottschade LA, Markovic SN. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer. 2009 Jan 1; 115(1):119-27.
    View PubMed
  43. Kottschade LA, Suman VJ, Lowe V, Markovic SN. Positron emission tomography in early detection of relapse in high-risk melanoma patients: A retrospective review. Community Oncol. 2009; 6(8):344-7.
    View PubMed
  44. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008 Jul; 44(11):1507-15. Epub 2008 Jun 18.
    View PubMed
  45. Thompson S, Bardia A, Tan A, Barton DL, Kottschade L, Sloan JA, Christensen B, Smith D, Loprinzi CL. Levetiracetam for the treatment of hot flashes: a phase II study. Support Care Cancer. 2008 Jan; 16 (1):75-82 Epub 2007 June 28
    View PubMed
  46. Kottschade L, Loprinzi C, Rao R. Vitamin e for the prevention of chemotherapy-induced peripheral neuropathy: rationale for an ongoing clinical trial. Support Cancer Ther. 2007 Sep 1; 4(4):251-3.
    View PubMed
  47. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun; 30(3):303-9.
    View PubMed
  48. Pruthi S, Thompson SL, Novotny PJ, Barton DL, Kottschade LA, Tan AD, Sloan JA, Loprinzi CL. Pilot evaluation of flaxseed for the management of hot flashes. J Soc Integr Oncol. 2007 Summer; 5(3):106-12.
    View PubMed
  49. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET, Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc. 2007 Apr; 82 (4):490-513
    View PubMed
  50. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET, Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007 Mar; 82(3):364-80.
    View PubMed
  51. Bardia A, Thompson S, Atherton PJ, Barton DL, Sloan JA, Kottschade LA, Christensen B, Collins M, Loprinzi CL. Pilot evaluation of aprepitant for the treatment of hot flashes. Support Cancer Ther. 2006 Jul 1; 3(4):240-6.
    View PubMed
  52. Perez DG, Loprinzi CL, Sloan J, Novotny P, Barton D, Carpenter L, Smith D, Christensen B, Rummans T. Pilot evaluation of bupropion for the treatment of hot flashes. J Palliat Med. 2006 Jun; 9(3):631-7.
    View PubMed
  53. Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006 Jan 15; 106(2):375-82.
    View PubMed
  54. Barton DL, Loprinzi C, Atherton PJ, Kottschade L, Collins M, Carpenter P, Adjei A, Rummans TA, Shanafelt T, Christensen B, Sloan J. Dehydroepiandrosterone for the treatment of hot flashes: a pilot study. Support Cancer Ther. 2006 Jan 1; 3(2):91-7.
    View PubMed
  55. Loprinzi CL, Flynn PJ, Carpenter LA, Atherton P, Barton DL, Shanafelt TD, Rummans TA, Sloan JA, Adjei AA, Mincey BA, Fitch TR, Collins M. Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med. 2005 Oct; 8(5):924-30.
    View PubMed
  56. Loprinzi CL, Barton DL, Carpenter LA, Sloan JA, Novotny PJ, Gettman MT, Christensen BJ. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc. 2004 Oct; 79(10):1247-51.
    View PubMed
  57. Barton D, Wilwerding M, Carpenter L, Loprinzi C. Libido as part of sexuality in female cancer survivors. Oncol Nurs Forum. 2004 May; 31(3):599-609.
    View PubMed